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Background: Melasma is a common hypermelanosis of the face. The use of a classical Q-switched ruby laser (QSRL)
to treat melasma is discussed controversially and is associated with frequent adverse effects, such as hyper- or
hypopigmentation. Recently a fractional-mode (FRx) QSRL was developed to minimize the adverse effects of
classical QSRL. The objective of this research was to evaluate the efficacy and safety of a novel FRx-QSRL in the
treatment of melasma in Caucasian patients.
Methods: We performed a retrospective study of 25 Caucasian melasma patients (Fitzpatrick skin types I to III).
Patients received one to three FRx-QSRL treatments (Tattoostar FRx, Asclepion Laser Technologies, Jena,
Germany) at pulse energies of 4 to 8 J/cm2. Three blinded investigators independently evaluated the melasma
area and severity index (MASI) score before treatment and at the four- to six-week follow-ups. At additional
three-month follow-ups, patients evaluated subjective improvement, pain and over-all satisfaction with the
treatment according to a numeric analogue score (NAS). Side effects were documented.
Results: At four to six weeks post laser treatment for a mean of 1.4 sessions, we observed a significant (P = 0.0001)
reduction of the MASI score from 6.54 to 1.98 (72.3%). Patients rated the pain of the intervention at a mean 2.46 points
(0 = no pain; 10 =maximum pain), the improvement at a mean 5.55 points (0 = no improvement; 10 =maximum
improvement) and the overall satisfaction at a mean 4.66 points (0 = not satisfied; 10 =maximum satisfaction). After three
months, post-inflammatory hyperpigmentation (PIH) and/or recurring melasma were observed in 7 (28%) and 11 (44%)
patients, respectively.
Conclusion: The 694-nm FRx-QSRL is a safe and effective option for treating melasma in Caucasian patients. Over periods
of >3 months, PIH and/or recurring melasma may develop at significant rates and may reduce patient satisfaction.
Multiple treatment sessions with lower pulse energies and/or a post-interventional therapy with hypopigmenting
ointments and UV protection may help to minimize these complications.Background
Melasma is a common acquired benign pigmentary dis-
order that classically manifests as symmetrical hyperme-
lanosis of the face. Most commonly melasma affects
women of reproductive age with darker skin types
(Fitzpatrick skin types IV and higher) but it may also
occur at other ages and in men. Briefly, the Fitzpatrick
skin type classification system is based on the color of
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reproduction in any medium, provided the orbeing the darkest (black)) and its response to UV expos-
ure (pigmentation) [1]. An estimated more than five mil-
lion people are affected by melasma in the United States
of America alone [2]. Melasma has a significant negative
impact on a patient’s quality of life [3]. Risk factors in-
clude ultraviolet (UV) exposure, hormonal alterations
(for example, pregnancy or oral contraceptives), thyroid
disease and anti-seizure medication. Melasma that is
related to pregnancy (or hormonal alterations) is also
referred to as chloasma.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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elusive. Established concepts propose a stimulation of
pigment-producing cells (melanocytes) by sex hormones
(estrogen and progesterone) and UV irradiation. Recent
studies have reported paracrine effects amongst melano-
cytes, keratinocytes and/or fibroblasts [4-7], and have
identified stem cell factor (SCF) and c-kit as pathogenic
factors. The authors propose that UV irradiation induces
SCF in dermal fibroblasts. Subsequently, the prolifera-
tion and melanogenesis of melanocytes is induced via
SCF/c-kit-induced signaling [8]. Hypopigmenting topical
agents containing hydroquinone, broad-spectrum UV
protection and camouflage are considered the current
standard of care for treating melasma. Additional thera-
peutic options include topical retinoic acids (tretinoin),
azelaic acid, microdermabrasion, chemical peeling or
electromagnetic devices, such as lasers [9-12].
Various laser and light systems, including ruby lasers,
Er:YAG lasers, carbon dioxide (CO2) lasers and intense
pulsed light (IPL), have been evaluated for their efficacy
in treating melasma [12-14]. IPL therapy effectively re-
duced the severity of melasma in a population of 89 Asian
women [15]. The use of conventional ablative laser systems
(Er:YAG and CO2) for treating melasma has been reported
to be associated with a significant frequency of post-
interventional hyper- as well as hypopigmentation
[16,17]. The frequency of adverse effects may be limited
by using novel fractional laser systems [18]. Notably,
several trials studying the effects of Q-switched ruby
lasers (QSRLs) have reported controversial results. In
1994, Taylor and Anderson noted that QSRLs were
ineffective for treating refractory melasma and post-
inflammatory hyperpigmentation [19]. A split-face study
by Tse et al. demonstrated that melasma patients devel-
oped post-inflammatory hyperpigmentation (PIH) and
worsening of the melasma after QSRL therapy [20].
Conversely, a recent study by Jang et al. reported that
a novel fractional-mode (FRx) QSRL (Tattoostar FRx,
Asclepion Laser Technologies, Jena, Germany) may be
effective in treating melasma in Korean patients [21].
Fractional photothermolysis has revolutionized laser
resurfacing (LSR) and was initially presented by Man-
stein and coworkers in 2004 [22]. The significant adverse
effects of classical LSR are significantly reduced by deliv-
ering the laser beam using a microarray. This technique
creates microscopic columns of treated tissue and inter-
vening areas of untreated skin, thereby allowing rapid
re-epithelialization and minimal downtime. Fractional
delivery has been developed for CO2, Er:YAG, and
yttrium scandium gallium garnet lasers [23]. Recently, a
fractional-mode QSRL has been developed (Tattoostar
FRx, Asclepion Laser Technologies, Jena, Germany),
which can homogeneously deliver ruby laser microspots.
The laser delivers a 7.1 × 7.1 mm2 array of 196microspots of 300 μm at a pulse duration of 40 ns, with
an overall coverage of 27.7%. This approach may
minimize the adverse effects of classical QSRL, such as
PIH and hypopigmentation. Here, we present a retro-
spective analysis of 25 Caucasian patients, which as-
sesses the efficacy of an FRx-QSRL in treating melasma.
Methods
Patients
In the study, 25 Caucasian women (mean age 39.8 years;
range 31 to 57; Fitzpatrick skin types I to III) with mel-
asma were treated with an FRx-QSRL (Tattoostar FRx,
Asclepion Laser Technologies, Jena, Germany) at the
Medical Skin Center, Düsseldorf, in 2010 and 2011. Pa-
tients presented with epidermal or mixed-type melasma.
Of the patients, 19 had had melasma <10 years and 6
had had it >10 years. The melasma areas were located
on the forehead (n = 14), the cheeks (n = 12), the chin
(n = 2) or the upper lip (n = 2). Identified risk factors
included past pregnancies (n = 5), hormonal therapy
(n = 12) and UV exposure (n = 25). Some patients pre-
sented with melasma in multiple locations and/or risk
factors.
Treatment
We used a 694-nm FRx-QSRL (Tattoostar FRx, Asclepion
Laser Technologies, Jena, Germany) at fluences of 4 to
8 J/cm2 and a frequency of 1 Hz. For each individual
patient, the fluence was gradually increased to identify
the minimal fluence needed to achieve a clinical effect
(photosdisruption). Each patient received laser treat-
ment for all affected areas. In pain-sensitive patients, a
topical anesthetic (a lidocaine-tetracaine mix) was
applied onto the treated areas 30 minutes prior to
treatment. However, most patients tolerated the inter-
vention without anesthesia. The laser treatment lasted
up to 10 minutes depending on the size and number of
treated areas. Post-intervention, cool packs were ap-
plied. Patients were advised to use strict UV protec-
tion. If more than one treatment was needed, the
patient received additional treatments after intervals of
four weeks.
Evaluation
Photographs (Canon EOS 40D digital camera, Tokyo
Japan) were taken before therapy and at the four- to six-
week follow-up sessions. Three blinded investigators in-
dependently evaluated the melasma area and severity
index (MASI) score before treatment and at the four- to
six-week follow-ups, as previously described [24]. At the
additional three-month follow-ups, patients evaluated
subjective improvement, pain and their overall satisfac-
tion with the treatment was determined according to a
Figure 1 Melasma in Caucasian patients before and four to six
weeks after one treatment with the 694-nm FRx-QSRL. (A) 39-
year old woman, fluence 6 J/cm2, front: 2 passes, cheeks: 1 pass. (B)
42-year-old woman, fluence 6 J/cm2, 1 pass. (C) 51-year-old woman,
fluence 6 J/cm2, 2 passes. (D) 42-year-old woman, fluence 5 J/cm2, 1
pass. Presented cases are representative examples of the 25 treated
patients. FRx, fractional-mode; QSRL, Q-switched ruby laser.
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effects were documented.
Statistical analysis
Student’s T-test was used for the statistical analysis, and
P < 0.05 was regarded as statistically significant.
Results
The analysis included 25 patients. At the follow-up at
four to six weeks after the last treatment (there were up
to three treatment sessions with a mean of 1.4 sessions)
the average MASI score showed a significant reduction
from 6.54 to 1.98 (72.3%) (Figures 1 and 2). In general,
the adverse effects for the first days post therapy were
mild and included erythema, a burning sensation, prur-
itus and exfoliation. After three months, PIH and/or re-
curring melasma were observed in 7 (28%) and 11 (44%)
patients, respectively.
The patients’ self-evaluation rated the pain of the
intervention at a mean 2.46 points (0 = no pain; 10 =
maximum pain), the improvement at a mean 5.55 points
(0 = no improvement; 10 =maximum improvement) and
the overall satisfaction at a mean 4.66 points (0 = not
satisfied; 10 = maximum satisfaction). We also used the
same protocol to treat patients with darker skin types
and melasma and/or PIH, with satisfactory results
(Figure 3).
Discussion
Laser therapy is based on the biophysical principle of se-
lective photothermolysis. The lasers used emit light at a
wavelength that is specifically and adequately absorbed
by the target chromophores [25]. The target chromo-
phore for pigmented lesions is melanin. Laser light that
is adequately absorbed by melanin includes that from
ruby (694 nm), Nd:YAG (523 and 1064 nm) and alexan-
drite (755 nm) lasers. Q-switched (QS) lasers generate a
rapid burst of light, which matches the thermal relax-
ation time for melanin, thereby effectively destroying the
pigment [14].
QS-Nd:YAG lasers have been shown to be effective
and are widely used in the management of melasma
[26-29]. A representative recent study by Zhou et al. of
50 patients (Fitzpatrick skin types IV to VI) demon-
strated a mean decrease in the MASI score of 61.3%
after nine sessions. At the three-month follow-up a
Figure 2 Melasma area and severity index (MASI) scores before
and four to six weeks after the final treatment with the 694-nm
FRx-QSRL. Values are plotted as individual ratios and mean ratios
are shown by the horizontal bar (*** P ≤ 0.0005). FRx, fractional-
mode; QSRL, Q-switched ruby laser.
Figure 3 Melasma in an African patient before and 12 weeks
after the final treatment with the 694-nm FRx-QSRL. 50-year
old woman; first session: fluence 6 J/cm2, 1 pass; second session:
fluence 7 J/cm2, 1 pass. The patient applied a combination of
topical bleaching agents and strict UV protection for the docu-
mented 12 post-intervention weeks. FRx, fractional-mode; QSRL,
Q-switched ruby laser.
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tients by Sim et al. reported improvement rates of 50%
to 74% [28]. For the QSRL, earlier reports state that the
laser is ineffective for melasma or may even worsen the
pigmentation after therapy [19,20]. Conversely, a recent
study by Jang et al. demonstrated a mean decrease of
the MASI score of 29.8% in 15 Korean patients after six
treatments with an FRx-QSRL (Tattoostar FRx, Asclepion
Laser Technologies, Jena, Germany). Two patients re-
ported a slight worsening. None of the patients reported
any long-term adverse effects such as PIH [21]. Jang et al.
found that a QSRL was more effective for treating mel-
asma compared to a QS-Nd:YAG laser [21]. This has been
demonstrated by comparative studies for other pigmented
lesions, such as nevus of Ota, lentigo, PIH and Becker’s
nevus, and it is proposed that this is due to the stronger
absorption of the 694-nm wavelength light (QSRL) by
melanin compared to 1064-nm wavelength light (QS-Nd:
YAG) [20,21,30].
Consistent with the results of Jang et al., we have dem-
onstrated a significant (P = 0.0001) decrease of the MASI
score of 72.3% in 25 Caucasian patients after a mean of
1.4 sessions with an FRx-QSRL (Tattoostar FRx, Ascle-
pion Laser Technologies, Jena, Germany). As the risk of
common adverse effects of QSRL therapy, such as PIH,
is expected to be significantly lower in Caucasian com-
pared to Asian skin types, we applied higher fluences
(4 to 8 J/cm2) per session compared to Jang et al. (2 to
3 J/cm2). However, this more aggressive treatment re-
sulted in a significantly higher rate of adverse effects
(PIH and/or recurring melasma in 28% and 44% of the
patients). Lower fluences and multiple treatment ses-
sions may reduce the frequency of these adverse effects.
However, many patients refuse further treatment (and
want to avoid additional costs) if the result of an initial
treatment is minimal. An additional option could be a
multimodal therapy using an FRx-QSRL in combination
with microdermabrasion [27], chemical peeling [31]
and/or hypopigmenting topical agents [32].Conclusions
In summary, the FRx-QSRL is a safe and effective treat-
ment for melasma for patients with Caucasian or Asian
skin types. Multimodal concepts may further increase
the efficacy and reduce the adverse effects of the ther-
apy. We maintained only a three-month follow-up after
the final treatment, so further long-term studies are
needed.Consent
Written informed consent was obtained from the patients
for the publication of this report and any accompanying
images.
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